Several cancers exploit this immune evasion strategy, and some authors have considered the blockade of CD47 on cancer cells or signal regulatory protein α (SIRPα) on macrophages as a valid therapeutic option (72, 73), also for PDAC to target pancreatic cancer stem cells and as adjuvant immunotherapy for liver micrometastasis (74, 75). This evidence concerns the gene CD47 and cancer.